{"id":43265,"date":"2026-07-23T17:00:00","date_gmt":"2026-07-23T15:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=e0f213a689beedef48a39bc5f404c9f6"},"modified":"2026-07-23T17:00:00","modified_gmt":"2026-07-23T15:00:00","slug":"revvity-announces-development-of-high-throughput-t-spot-tb-automated-platform-for-clinical-labs","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=43265","title":{"rendered":"Revvity Announces Development of High-Throughput T-SPOT.TB Automated Platform for Clinical Labs"},"content":{"rendered":"<ul class=\"bwlistdisc\">\n<li>\n<b><i>New T-SPOT A201 platform engineered to deliver high-volume latent tuberculosis IGRA testing to meet the needs of high-throughput laboratories<\/i><\/b><\/li>\n<li>\n<b><i>Intends to provide labs with a more highly automated workflow designed to support the performance characteristics associated with the T-SPOT.TB assay<\/i><\/b><\/li>\n<li>\n<b><i>Built on the success of the Auto-Pure 2400 liquid handler, the platform is engineered as an accessible, scalable and efficient solution<\/i><\/b><\/li>\n<\/ul><p>WALTHAM, Mass.--(BUSINESS WIRE)--<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.revvity.com%2F&amp;esheet=54574591&amp;newsitemid=20260723438314&amp;lan=en-US&amp;anchor=Revvity%2C+Inc.&amp;index=1&amp;md5=74e064c3b5535ecf23842fafe9c4d449\" rel=\"nofollow\" shape=\"rect\">Revvity, Inc.<\/a> today announced the development of the T-SPOT\u2122 A201, a next-generation high-throughput automated platform designed to support the performance advantages of <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.revvity.com%2Fcategory%2Fautomate-t-spottb-workflow&amp;esheet=54574591&amp;newsitemid=20260723438314&amp;lan=en-US&amp;anchor=T-SPOT.TB%26%238482%3B&amp;index=2&amp;md5=ae8db2b786d2165da767d6879e636be6\" rel=\"nofollow\" shape=\"rect\">T-SPOT.TB\u2122<\/a> testing for large-volume clinical labs, enabling a reliable, accurate solution for latent tuberculosis (TB) detection.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260723438314\/en\/1801356\/5\/rev_logo_rgb_black_%282%29.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260723438314\/en\/1801356\/22\/rev_logo_rgb_black_%282%29.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260723438314\/en\/1801356\/5\/rev_logo_rgb_black_%282%29.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260723438314\/en\/1801356\/21\/rev_logo_rgb_black_%282%29.jpg\" \/><\/a><p>\nTuberculosis remains a critical global health challenge, with testing demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and broader public health programs. It is crucial for labs to deliver accurate results upon initial testing, while managing a high volume of samples to support timely treatment and improved patient outcomes.<\/p><p>\nBuilding on the success of <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.revvity.com%2Fpress-announcements%2Fpress-releases%2Fpress-release-details%2F2025%2FRevvity-Secures-FDA-Approval-for-Improved-Automated-Latent-Tuberculosis-Test%2Fdefault.aspx&amp;esheet=54574591&amp;newsitemid=20260723438314&amp;lan=en-US&amp;anchor=the+Auto-Pure+2400+liquid+handler%2C&amp;index=3&amp;md5=380bc4432a104ea52dea28dea999949f\" rel=\"nofollow\" shape=\"rect\">the Auto-Pure 2400 liquid handler,<\/a> the T-SPOT A201 platform is engineered to meet the throughput requirements of large-scale testing environments, strengthening the Company\u2019s automation portfolio and its ability to support labs across a range of throughput needs. It can process up to 384 samples per instrument in an 8-hour shift, with 45 seconds per sample of hands-on time \u2013 the lowest of any T-SPOT automation solution. The platform aims to ensure that these labs benefit from the scalability and workflow advantages associated with automated T-SPOT.TB testing.<\/p><p>\n\u201cThe T-SPOT A201 automation platform represents a significant step forward in making the benefits of T-SPOT.TB testing accessible at scale,\u201d said Steven Hart, vice president and general manager of infectious disease diagnostics at Revvity. \u201cOur development program is focused on delivering a solution that gives high-volume clinical labs the performance, workflow efficiency, and competitive economics they need.\u201d<\/p><p>\nAdditional studies on the performance of the Company\u2019s automation solutions will be released in the coming months. The T-SPOT A201 platform is currently under development and targeted for launch in the second half of 2027, subject to regulatory approval.<\/p><p>\nRevvity\u2019s Euroimmun business will be showcasing its latest automation solutions at the ADLM 2026 conference in Anaheim, California from July 26 \u2013 30 at booth #1411, with a T-SPOT.TB breakfast workshop on July 28. To register, please visit the website <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmarketing.us.euroimmun.info%2FADLM2026&amp;esheet=54574591&amp;newsitemid=20260723438314&amp;lan=en-US&amp;anchor=here&amp;index=4&amp;md5=b7a525e19b23f2d86efd516871929743\" rel=\"nofollow\" shape=\"rect\">here<\/a>.<\/p><p>\n<i>The T-SPOT A201 platform is currently under development and not yet available for sale.<\/i><\/p><p>\n<b>About Revvity<\/b><\/p><p>\nAt Revvity, \u201cimpossible\u201d is inspiration, and \u201ccan\u2019t be done\u201d is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what\u2019s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.<\/p><p>\nWith 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&amp;P 500 index and has customers in more than 160 countries.<\/p><p>\nStay updated by following our <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fnews.revvity.com%2F&amp;esheet=54574591&amp;newsitemid=20260723438314&amp;lan=en-US&amp;anchor=Newsroom&amp;index=5&amp;md5=c21e20faa4fb0ebe9e54b7d5899aa04e\" rel=\"nofollow\" shape=\"rect\">Newsroom<\/a>, <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Frevvity%2F&amp;esheet=54574591&amp;newsitemid=20260723438314&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=3d3c5776a4696445c3469252b1efd592\" rel=\"nofollow\" shape=\"rect\">LinkedIn<\/a>, <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FRevvityInc&amp;esheet=54574591&amp;newsitemid=20260723438314&amp;lan=en-US&amp;anchor=X&amp;index=7&amp;md5=f061d71ac32207cd31950f1aabc38e65\" rel=\"nofollow\" shape=\"rect\">X<\/a>, <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fchannel%2FUCUqLrqOpUUwhz3UaLn78tVQ&amp;esheet=54574591&amp;newsitemid=20260723438314&amp;lan=en-US&amp;anchor=YouTube&amp;index=8&amp;md5=6b88bb2f4c70fe6fe6c505bd8f1255e8\" rel=\"nofollow\" shape=\"rect\">YouTube<\/a>, <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FRevvityInc&amp;esheet=54574591&amp;newsitemid=20260723438314&amp;lan=en-US&amp;anchor=Facebook&amp;index=9&amp;md5=8a8f0f6072c6091dba9a1dc6f737333c\" rel=\"nofollow\" shape=\"rect\">Facebook<\/a> and <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Frevvity%2F&amp;esheet=54574591&amp;newsitemid=20260723438314&amp;lan=en-US&amp;anchor=Instagram&amp;index=10&amp;md5=ae15ee4c548074af8b8140a7d96a1d88\" rel=\"nofollow\" shape=\"rect\">Instagram<\/a>.<\/p><br\/> <b>Contacts<\/b> <br\/><p>\n<b>Media Relations:<\/b><br\/>Chet Murray\n<br\/>(781) 462-5126\n<br\/><a  href=\"mailto:chet.murray@revvity.com\" rel=\"nofollow\" shape=\"rect\">chet.murray@revvity.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>New T-SPOT A201 platform engineered to deliver high-volume latent tuberculosis IGRA testing to meet the needs of high-throughput laboratories<\/p>\n<p>Intends to provide labs with a more highly automated workflow designed to support the performance character&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-43265","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/43265","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43265"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/43265\/revisions"}],"predecessor-version":[{"id":43266,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/43265\/revisions\/43266"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43265"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43265"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43265"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}